With our in-house technology platform, scientific expertise in the inner ear, and network of experts, Sensorion can continually develop and optimize its pipeline and market expertise. Consequently, we are poised to expand our pipeline and facilitate other pharmaceutical collaborations.

We select and develop drug candidates from a pool of compounds in late pre-clinical and clinical stage development obtained from partnerships, collaborations and publically available drug libraries.

SENS-401 is currently being evaluated in a Phase 2 clinical trial for SSNHL and Phase 2 ready for Cisplatin-Induced ototoxicity (CIO)

20190603 pipeline


Latest news

  • 19 Feb 2020

    Sensorion appoints gene therapy expert Dr Géraldine Honnet as Chief Medical Officer. Read

  • 17 Feb 2020

    Sensorion Receives Ethics Committee Approval to Include New Military Sites in SENS-401 Phase 2 study. read

Patient center

Corporate presentation